|
ISTANBUL (TURKEY): The
European College of Neuropsychopharmacology (ECNP) promotes new
discoveries in brain research and mental disorders. It is holding its
22nd congress here at Istanbul Convention & Exhibition Centre (ICEC)
during September 2009. Salient features of the congress will be
highlighted at Press Conferences on September 13, 14 and 15th. The
topics which will figure prominently during the congress include future
of schizophrenia, role of genetic factors in adult ADHD and Monoamine
Oxidases and its relationship to personality traits and antisocial
behaviour.
According to the organizers it is expected that more than 6,500 clinical
and basic scientists such as psychiatrists, neurologists, psychologists
and neuroscience researchers from all over the world will attend the
ECNP Congress, which is the largest annual high scientific standard
congress on mental disorders and Neuropsychopharmacology in Europe.
Renowned experts from 25 countries will present and discuss the latest
breakthroughs and new perspectives covering virtually all disorders of
the brain, as well as discuss the various aspects of pharmacotherapy and
their impact on patients´ quality of life.
The most exciting topics and findings of the high-caliber and well-
balanced programme of the 22nd ECNP Congress will be presented at three
press conferences to be held during the congress at the conference
venue. Each press conference will be moderated by an expert of ECNP. At
the three press conferences renowned experts from research centers in
Europe and the USA will present their outstanding research findings.
Details of the press conferences are as under:
Sunday, 13 September 2009: Monoamine oxidases: relationship to
personality traits and antisocial behaviour by Professor Lars Oreland,
M.D., Ph.D., Sweden
Monday, 14 September 2009: The future of schizophrenia by Professor
William T. Carpenter Jr., M.D., USA
Tuesday, 15 September 2009: The role of genetic factors in adult ADHD by
Assoc. Prof. Barbara Franke, Ph.D., The Netherlands. |
